Capital Cell

Capital Cell is a prominent European equity crowdfunding platform dedicated to fostering innovation within the biotechnology and life sciences sectors. The firm specializes in connecting early-stage companies with a diverse network of private investors, aiming to democratize access to high-impact and high-return investment opportunities in human health. They meticulously vet potential investments, with only 3% of applicant companies making it to their platform, ensuring a focus on promising ventures.

Founded in Barcelona, Spain, in 2015 by Daniel Oliver, Capital Cell emerged from the city's vibrant scientific ecosystem. The firm's mission is to drive global innovation in health and biotechnology by enabling individuals and specialized funds to contribute to groundbreaking scientific research. This approach not only seeks financial returns but also emphasizes making a significant societal impact through advancements in healthcare.

Capital Cell's portfolio showcases a range of innovative companies, including METHYS Dx, which focuses on real-time cancer patient monitoring; Oragen, developing oral RNA technology for inflammatory bowel diseases; and AbTx, working on advanced anti-cancer treatments. Other notable investments span areas like gene delivery (EVIS Bioscience), bone reconstruction (Kervalion), rehabilitation through VR and AI (DynamicsVR), stroke treatment (FreeOx), early Multiple Sclerosis diagnosis (ALA Diagnostics), cell and gene therapy (Alaya.bio), and ALS treatment (AXOLTIS Pharma).

The firm boasts a robust team and an extensive BioExpert Network comprising over 3,500 scientists, doctors, and investment experts. Key team members include Daniel Oliver (Founder and Director), Julien Gillet-Daubin (Director, France), Heidi Rohwer (BioExpert Network Coordinator), and Judith Benoit (Investment Manager), among others. This multidisciplinary expertise underpins their rigorous due diligence process, which includes in-depth analysis of business plans, financial reviews, patent assessments, and regulatory strategies, ensuring that investments are thoroughly evaluated and supported post-investment.